Literature DB >> 16797291

Tacrolimus-associated hypomagnesemia in renal transplant recipients.

S D Navaneethan1, S Sankarasubbaiyan, M D Gross, V Jeevanantham, R D Monk.   

Abstract

BACKGROUND: Since hypomagnesemia occurs frequently in tacrolimus treated patients, we studied the correlation between renal magnesium wasting and tacrolimus blood levels in renal transplant patients.
METHODS: Serum magnesium, fractional excretion of magnesium (FEMg), and 24-hour urinary excretion of magnesium were measured in 41 transplant patients and 10 healthy volunteers for correlation with tacrolimus level.
RESULTS: Of tacrolimus-treated patients, 43% displayed hypomagnesemia. FEMg (7.42+/-3.59% versus 1.88+/-0.43%) and 24-hour urinary excretion (112.36+/-51.43 mg/dL versus 6.7+/-2.79 mg/dL) were significantly higher among tacrolimus-treated patients than controls. Magnesium replacement did not influence FEMg or 24-hour urinary magnesium excretion. Tacrolimus level was the best predictor of 24-hour urinary magnesium excretion and FEMg. Serum magnesium levels correlated inversely with tacrolimus concentrations and creatinine clearance.
CONCLUSION: Hypomagnesemia in renal transplant recipients results from renal magnesium wasting. Tacrolimus levels and renal function impact on the excess renal magnesium excretion. Studies of longer duration are warranted to assess the long-term effects of this early posttransplant hypomagnesemia.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16797291     DOI: 10.1016/j.transproceed.2006.02.077

Source DB:  PubMed          Journal:  Transplant Proc        ISSN: 0041-1345            Impact factor:   1.066


  13 in total

1.  Proton-pump inhibitors do not influence serum magnesium levels in renal transplant recipients.

Authors:  Charlotte Van Ende; Steven Van Laecke; Celine Marechal; Francis Verbeke; Nada Kanaan; Eric Goffin; Raymond Vanholder; Michel Jadoul
Journal:  J Nephrol       Date:  2014-05-10       Impact factor: 3.902

Review 2.  Hypomagnesemia in the Cancer Patient.

Authors:  Biruh T Workeneh; Nupur N Uppal; Kenar D Jhaveri; Helbert Rondon-Berrios
Journal:  Kidney360       Date:  2020-11-11

Review 3.  What is the impact of immunosuppressive treatment on the post-transplant renal osteopathy?

Authors:  Kristina Blaslov; Lea Katalinic; Petar Kes; Goce Spasovski; Ruzica Smalcelj; Nikolina Basic-Jukic
Journal:  Int Urol Nephrol       Date:  2013-11-12       Impact factor: 2.370

Review 4.  Post-Transplant Diabetes Mellitus: Causes, Treatment, and Impact on Outcomes.

Authors:  Vijay Shivaswamy; Brian Boerner; Jennifer Larsen
Journal:  Endocr Rev       Date:  2015-12-09       Impact factor: 19.871

5.  Hypomagnesemia and the Risk of New-Onset Diabetes Mellitus after Kidney Transplantation.

Authors:  Johnny W Huang; Olusegun Famure; Yanhong Li; S Joseph Kim
Journal:  J Am Soc Nephrol       Date:  2015-10-08       Impact factor: 10.121

Review 6.  Adverse effects of immunosuppression in pediatric solid organ transplantation.

Authors:  Kristine S Schonder; George V Mazariegos; Robert J Weber
Journal:  Paediatr Drugs       Date:  2010       Impact factor: 3.022

7.  Effect of mycophenolate mofetil on plasma bioelements in renal transplant recipients.

Authors:  Jolanta Kamińska; Joanna Sobiak; Joanna Maria Suliburska; Grażyna Duda; Maciej Głyda; Zbigniew Krejpcio; Maria Chrzanowska
Journal:  Biol Trace Elem Res       Date:  2011-08-26       Impact factor: 3.738

8.  Hypomagnesemia and increased risk of new-onset diabetes mellitus after transplantation in pediatric renal transplant recipients.

Authors:  Wesley Hayes; Sheila Boyle; Adrian Carroll; Detlef Bockenhauer; Stephen D Marks
Journal:  Pediatr Nephrol       Date:  2016-12-30       Impact factor: 3.714

Review 9.  Nutritional Requirements of Lung Transplant Recipients: Challenges and Considerations.

Authors:  Valerie Jomphe; Larry C Lands; Genevieve Mailhot
Journal:  Nutrients       Date:  2018-06-19       Impact factor: 5.717

10.  Improving Transplant Medication Safety Through a Technology and Pharmacist Intervention (ISTEP): Protocol for a Cluster Randomized Controlled Trial.

Authors:  Casey L Hall; Cory E Fominaya; Mulugeta Gebregziabher; Sherry K Milfred-LaForest; Kelsey M Rife; David J Taber
Journal:  JMIR Res Protoc       Date:  2019-10-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.